Journal: Immunotherapy
This review outlines the current state and future directions of immunotherapy in cervical cancer, focusing on strategies to overcome resistance and expand benefit beyond the subset of patients with clearly “hot,” PD‑L1–positive tumors.
Key points:
- Current role of immune checkpoint inhibitors (ICIs):
Agents such as pembrolizumab and cemiplimab have been incorporated into the management of locally advanced and recurrent/metastatic cervical cancer.
Their use has translated into meaningful survival improvements in selected patients.
- Limitations and resistance:
Both primary and acquired resistance significantly limit the durability and breadth of benefit.
Resistance is particularly problematic in patients with low PD‑L1 expression and immunologically “cold” tumors with poor immune infiltration.
- Emerging strategies to overcome resistance:
The review discusses several complementary approaches aimed at reshaping the tumor–immune interaction:
- Novel checkpoint targets: Expanding beyond PD‑1/PD‑L1 to alternative inhibitory and costimulatory pathways to enhance T‑cell activity.
- Tumor microenvironment modulation: Approaches intended to convert “cold” tumors into “hot” ones, improving immune cell infiltration and function.
- Therapeutic cancer vaccines: HPV‑targeted and other vaccine platforms designed to induce or amplify tumor‑specific immune responses.
- Adoptive cell therapies: Strategies such as engineered or expanded T cells to directly boost tumor‑reactive immunity.
- Combination approaches and future directions:
Early clinical signals suggest synergy when combining ICIs with vaccines, cell therapies, or microenvironment‑modulating agents.
The field is moving toward rational combinations, optimized sequencing/timing, and biomarker‑driven patient selection.
Ongoing trials and translational work are expected to clarify which combinations, in which settings and populations, will yield durable benefit.
Overall, the article positions cervical cancer immunotherapy as a rapidly evolving area where next‑generation agents and rational combinations may substantially broaden and deepen responses beyond what current checkpoint blockade alone can achieve.